Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
831
mi
from 43215
Tampa, FL
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
831
mi
from 43215
Tampa, FL
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
561
mi
from 43215
Savannah, GA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
561
mi
from 43215
Savannah, GA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
167
mi
from 43215
Indianapolis, IN
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
167
mi
from 43215
Indianapolis, IN
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
620
mi
from 43215
Kansas City, KA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
188
mi
from 43215
Louisville, KY
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
188
mi
from 43215
Louisville, KY
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
767
mi
from 43215
Covington, LA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
767
mi
from 43215
Covington, LA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
394
mi
from 43215
St. Louis, MO
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
394
mi
from 43215
St. Louis, MO
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
307
mi
from 43215
Winston-Salem, NC
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
307
mi
from 43215
Winston-Salem, NC
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
98
mi
from 43215
Cincinnati, OH
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
70
mi
from 43215
Miamisburg, OH
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
70
mi
from 43215
Miamisburg, OH
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
351
mi
from 43215
Greer, SC
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
351
mi
from 43215
Greer, SC
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
524
mi
from 43215
Mt. Pleasant, SC
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
524
mi
from 43215
Mt. Pleasant, SC
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
906
mi
from 43215
Dallas, TX
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
906
mi
from 43215
Dallas, TX
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
995
mi
from 43215
Houston, TX
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
995
mi
from 43215
Houston, TX
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
1138
mi
from 43215
San Antonio, TX
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1138
mi
from 43215
San Antonio, TX
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
426
mi
from 43215
Norfolk, VA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
426
mi
from 43215
Norfolk, VA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
335
mi
from 43215
Richmond, VA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
335
mi
from 43215
Richmond, VA
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Clinical Research Facility
308
mi
from 43215
Kenosha, WI
MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162 AM2)
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
308
mi
from 43215
Kenosha, WI
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects With Severe Hypertriglyceridemia
Status: Archived
Illinois Recruiting
293
mi
from 43215
Chicago, IL
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Assess Efficacy and Safety of AKR-963 Therapy in Subjects With Severe Hypertriglyceridemia
Status: Archived
Updated: 1/1/1970
Illinois Recruiting
293
mi
from 43215
Chicago, IL
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Radiant Research Inc.
274
mi
from 43215
Chicago, IL
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Updated: 1/1/1970
Radiant Research Inc.
274
mi
from 43215
Chicago, IL
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Clinical Trial Facility
620
mi
from 43215
Kansas City, KA
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
620
mi
from 43215
Kansas City, KA
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Hematology Oncology Associates of the Quad Cities
405
mi
from 43215
Bettendorf, IA
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
405
mi
from 43215
Bettendorf, IA
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Clinical Trial Facility
394
mi
from 43215
St Louis, MO
Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
A 12-Week, Double-Blind, Randomized, Placebo-Controlled Study to Assess the LDL Cholesterol Lowering and Anti-Hyperglycemic Efficacy of Welchol® (Colesevelam) in Subjects With Impaired Fasting Glucose Who Are Taking Niaspan® (Niacin) for Dyslipidemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
394
mi
from 43215
St Louis, MO
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status: Archived
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
341
mi
from 43215
Centralia, IL
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status: Archived
Clinical Trial Facility
188
mi
from 43215
Louisville, KY
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
188
mi
from 43215
Louisville, KY
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status: Archived
Clinical Trial Facility
809
mi
from 43215
Ellsworth, ME
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
809
mi
from 43215
Ellsworth, ME
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status: Archived
Clinical Trial Facility
344
mi
from 43215
Richmond, VA
Epanova® for Lowering Very High Triglycerides
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
344
mi
from 43215
Richmond, VA
Endothelial Hyperpolarization in Humans
Physiology and Pathologic Role of Endothelium-Derived Hyperpolarizing Factor in Humans
Status: Enrolling
Updated:  12/31/1969
Emory University School of Medicine
432
mi
from 43215
Atlanta, GA
Endothelial Hyperpolarization in Humans
Physiology and Pathologic Role of Endothelium-Derived Hyperpolarizing Factor in Humans
Status: Enrolling
Updated: 12/31/1969
Emory University School of Medicine
432
mi
from 43215
Atlanta, GA
Click here to add this to my saved trials
Novel Therapies for Metabolic Complications of Lipodystrophies
Novel Therapies for Metabolic Complications in Patients With Lipodystrophies
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Novel Therapies for Metabolic Complications of Lipodystrophies
Novel Therapies for Metabolic Complications in Patients With Lipodystrophies
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol
A Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy Metabolism
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol
A Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy Metabolism
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol
A Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy Metabolism
Status: Enrolling
Updated:  12/31/1969
University of Maryland Amish Research
355
mi
from 43215
Lancaster, PA
The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol
A Nutrigenomics Intervention for the Study of the Role of Dietary Sitosterol on Lipid, Glucose and Energy Metabolism
Status: Enrolling
Updated: 12/31/1969
University of Maryland Amish Research
355
mi
from 43215
Lancaster, PA
Click here to add this to my saved trials
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women
Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Phytosterols, Ezetimibe, and Cholesterol Metabolism
Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3)
Status: Enrolling
Updated:  12/31/1969
Center for Advance Nutrition at Utah State University
1507
mi
from 43215
Logan, UT
Phytosterols, Ezetimibe, and Cholesterol Metabolism
Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3)
Status: Enrolling
Updated: 12/31/1969
Center for Advance Nutrition at Utah State University
1507
mi
from 43215
Logan, UT
Click here to add this to my saved trials
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
A Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Whole Body Insulin Sensitivity in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
A Randomized Comparison of the Acute Effects of Olanzapine and Ziprasidone on Whole Body Insulin Sensitivity in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
397
mi
from 43215
Saint Louis, MO
Click here to add this to my saved trials
Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine
Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
524
mi
from 43215
Charleston, SC
Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine
Prevention of Weight Gain and Dyslipidemia by Green Tea in Patients Initiating Therapy With Olanzapine
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
524
mi
from 43215
Charleston, SC
Click here to add this to my saved trials
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
The RIGHT Study: Risk Stratification With Image Guidance of HMG Coa Reductase Inhibitor Therapy
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
The RIGHT Study: Risk Stratification With Image Guidance of HMG Coa Reductase Inhibitor Therapy
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
322
mi
from 43215
Bethesda, MD
Click here to add this to my saved trials
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
California Clinical Trials Medical Group
mi
from 43215
Culver City, CA
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
California Clinical Trials Medical Group
mi
from 43215
Culver City, CA
Click here to add this to my saved trials
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Glendale Adventist Medical Center
1968
mi
from 43215
Glendale, CA
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Glendale Adventist Medical Center
1968
mi
from 43215
Glendale, CA
Click here to add this to my saved trials
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
SeaView Research Inc.
996
mi
from 43215
Miami, FL
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
SeaView Research Inc.
996
mi
from 43215
Miami, FL
Click here to add this to my saved trials
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Covance Clinical Research Unit, Inc.
4501
mi
from 43215
Honolulu, HI
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Covance Clinical Research Unit, Inc.
4501
mi
from 43215
Honolulu, HI
Click here to add this to my saved trials
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Vince and Associates Clinical Research
338
mi
from 43215
Overland Park, KA
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Vince and Associates Clinical Research
338
mi
from 43215
Overland Park, KA
Click here to add this to my saved trials
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Prism Research Inc.
617
mi
from 43215
Saint Paul, MN
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Prism Research Inc.
617
mi
from 43215
Saint Paul, MN
Click here to add this to my saved trials
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated:  12/31/1969
Healthcare Discoveries, LLC/ICON Development Solutions
1138
mi
from 43215
San Antonio, TX
Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of Pf-04950615 In Healthy Adult Subjects With Hypercholesterolemia
Status: Enrolling
Updated: 12/31/1969
Healthcare Discoveries, LLC/ICON Development Solutions
1138
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1655
mi
from 43215
Chandler, AZ
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1655
mi
from 43215
Chandler, AZ
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2109
mi
from 43215
Greenbrae, CA
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2109
mi
from 43215
Greenbrae, CA
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
2107
mi
from 43215
Santa Rosa, CA
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
2107
mi
from 43215
Santa Rosa, CA
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
668
mi
from 43215
Jacksonville, FL
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
668
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
274
mi
from 43215
Chicago, IL
Click here to add this to my saved trials
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
460
mi
from 43215
Iowa City, IA
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
460
mi
from 43215
Iowa City, IA
Click here to add this to my saved trials